Notes to Accounts of Saroja Pharma Industries India Ltd.

Mar 31, 2024

The Authorised Equity Share Capital of the company was increased from 10,000 Equity Shares of Rs.10/- each to 2,50,000 Equity Shares of Rs. 10/-each vide resolution passed in EGM dated 23/02/2022.

Further Authorised Equity Share Capital of the company was increased from 2,50,000 Equity Shares of Rs.10/- each to 50,00,000 Equity Shares of Rs. 10/- each vide resolution passed in EGM dated 21/12/2022.

The Company issued 15,822 Equity Shares of Rs. 10/- each at Rs. 1106/-converting existing Loan from director into Equity vide Board Resolution dated 28/02/2020.

The Company issued 2,00,000 Equity Shares of Rs. 10/- each for cash at face value vide against Right Issue Board Resolution dated 23/06/2021.

The Company bonus shares issued 27,09,864 Equity Shares of Rs. 10/- each vide Board Resolution dated 08/02/2023.

The company has issued Initial Public Issue Offer (IPO) of 1084800 equity shares of face value of Rs.10/= at a premium of Rs.74/= each at an issue price of Rs.84/= per Share. on 13th September 2023.

The Company has utilized Security Premium of Rs.43.57 Lakhs Out of Rs.802.75 Lakhs towards expenses incurred for raising IPO NOTE 2B: Term/rights attached to equity shares:

The Company has only one class of equity shares having a par value of Rs10 per share. Holder of each equity share is entitled to one vote. The Company declares and pays dividends in Indian Rupees. The dividend proposed by the board of directors is subject to the approval of shareholders at the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution to equity shareholders will be in proportion to the number of equity shares held by the shareholders.

During the year, the company successfully completed its initial public offering (IPO), pursuant to which 10,84,800 equity shares of Rs.10 each were alloted at an issued price of Rs.84.00 per equity share. The Company received approval from NSE, and its share have been listed on the NSE SME Platform effective from 13th September, 2023. The gross proceeds from the IPO aggregated to Rs.911.23 Lakhs. As of 31st March 2024, the unutilized amount of Rs. 372.88 from IPO proceeds was kept in the company''s Cash Credit (CC) account.

NOTE 29 - CONTIGENT LIABILITIES RESTATED STATEMENT OF CONTINGENT LIABILITIES
Particulars	As at 31.03.2024	As at 31.03.2023
Claims against the company not acknowledged as Debts	Unascertainable	Unascertainable
Bank Guarantee (Financial)	NIL	NIL
Bank Guarantee (Performance)	NIL	NIL
Income Tax Demand	NIL	NIL
TDS Demand	NIL	NIL
Sales Tax Pending Cases	NIL	NIL
Gst contingenet liability on account of mismatch in 2A, 2B, and 3B	NIL	NIL
Other moneys for which the Company is contingently liable	NIL	NIL
Commitments (to the extent not provided for)	NIL	NIL
Estimated amount of contract remaining to be executed on capital account and not provided for	NIL	NIL
Uncalled liability on shares and other investments partly paid	NIL	NIL
Other commitments	NIL	NIL
Total	NIL	NIL

Note 31

Trade Receivable, Trade Payable, Short Term Borrowings and Short Term Loans and Advances are subject to confirmantion and reconciliation.

Note 32

As per information available with the Company, none of the creditors has confirmed that they are registeered under the Micro, Small and Medium enterprises Development Act, 2006

Note 33

Balances of Debtors, Loans and Advances, Secured Loans, Sundry Creditors & Others are subjct to confirmation and reconcilation and consequential adjustments, if any.

Note 34

In the opinion of the Board & to the best of their knowledge & belief the value of realization of current assets, loans & advances in the ordinary course of business world not be less than the amount at which they are stated in the Balance Sheet & the provisions for all the loans & determined liabilities is adequate and not in escess of the amount.

Note 35

Previous year figures have been recasted / restated where necessary.